Evidence map›Paper›PMID 38443394›Full record

ArticleNature communications2024

Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing.

Fei Deng, Yi Li, Biyao Yang, Rui Sang, Wei Deng, Maya Kansara, Frank Lin, Subotheni Thavaneswaran, David M Thomas, Ewa M Goldys

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
25.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 110 citations in OpenAlex.

  1. Molecular mechanisms and biotechnology applications of CRISPR-Cas12a.Nature reviews. Molecular cell biology · 2026
    Review
  2. Article
  3. A Dual-Channel Synergistic Ultrasensitive Biosensor for Tumor Liquid Biopsy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Review
  5. Review
  6. Towards deployable CRISPR-based nucleic acid detection.Progress in biomedical engineering (Bristol, England) · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Advances in nanozyme-assisted CRISPR diagnostic technology.Frontiers in bioengineering and biotechnology · 2026
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Fei Deng *Graduate School of Biomedical Engineering, Faculty of Engineering, University of New South Wales, Sydney, NSW, 2052, Australia.ORCID 0000-0002-5606-0278
Yi Li *Graduate School of Biomedical Engineering, Faculty of Engineering, University of New South Wales, Sydney, NSW, 2052, Australia. yi.li6@unsw.edu.au.ORCID 0000-0003-2226-5918
Biyao YangGraduate School of Biomedical Engineering, Faculty of Engineering, University of New South Wales, Sydney, NSW, 2052, Australia.
Rui SangGraduate School of Biomedical Engineering, Faculty of Engineering, University of New South Wales, Sydney, NSW, 2052, Australia.ORCID 0000-0001-8557-2072
Wei DengSchool of Biomedical Engineering, University of Technology Sydney, Sydney, NSW, 2007, Australia.
Maya KansaraGarvan Institute of Medical Research, Darlinghurst, Sydney, NSW, 2011, Australia.
Frank LinGarvan Institute of Medical Research, Darlinghurst, Sydney, NSW, 2011, Australia.ORCID 0000-0001-9250-6874
Subotheni ThavaneswaranGarvan Institute of Medical Research, Darlinghurst, Sydney, NSW, 2011, Australia.
David M ThomasGarvan Institute of Medical Research, Darlinghurst, Sydney, NSW, 2011, Australia.ORCID 0000-0002-2527-5428
Ewa M GoldysGraduate School of Biomedical Engineering, Faculty of Engineering, University of New South Wales, Sydney, NSW, 2052, Australia.ORCID 0000-0003-2470-7118
UNSW Sydney · AUGarvan Institute of Medical Research · AUThe University of Sydney · AUUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Control of CRISPR/Cas12a trans-cleavage is crucial for biosensor development. Here, we show that small circular DNA nanostructures which partially match guide RNA sequences only minimally activate Cas12a ribonucleoproteins. However, linearizing these structures restores activation. Building on this finding, an Autocatalytic Cas12a Circular DNA Amplification Reaction (AutoCAR) system is established which allows a single nucleic acid target to activate multiple ribonucleoproteins, and greatly increases the achievable reporter cleavage rates per target. A rate-equation-based model explains the observed near-exponential rate trends. Autocatalysis is also sustained with DNA nanostructures modified with fluorophore-quencher pairs achieving 1 aM level (<1 copy/μL) DNA detection (10

Indexed as

Helicobacter pyloriNanostructuresCRISPR-Cas SystemsDNADNA, CircularRibonucleoproteinsRNARNA, Guide, CRISPR-Cas SystemsDNADNA, CircularRibonucleoproteinsRNARNA, Guide, CRISPR-Cas Systems

Identifiers

PMID38443394
PMCPMC10914725
OpenAlexW4392460269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.